SK279557B6 - Deriváty indolizínu, spôsob ich prípravy a farmace - Google Patents
Deriváty indolizínu, spôsob ich prípravy a farmace Download PDFInfo
- Publication number
- SK279557B6 SK279557B6 SK977-87A SK97787A SK279557B6 SK 279557 B6 SK279557 B6 SK 279557B6 SK 97787 A SK97787 A SK 97787A SK 279557 B6 SK279557 B6 SK 279557B6
- Authority
- SK
- Slovakia
- Prior art keywords
- indolizine
- methyl
- pharmaceutically acceptable
- ethyl
- isopropyl
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 35
- 239000000203 mixture Substances 0.000 title claims abstract description 28
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 230000008569 process Effects 0.000 title claims description 26
- 125000003406 indolizinyl group Chemical class C=1(C=CN2C=CC=CC12)* 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 103
- 150000002478 indolizines Chemical class 0.000 claims abstract description 28
- HOBCFUWDNJPFHB-UHFFFAOYSA-N indolizine Chemical compound C1=CC=CN2C=CC=C21 HOBCFUWDNJPFHB-UHFFFAOYSA-N 0.000 claims abstract description 14
- 238000009835 boiling Methods 0.000 claims abstract description 10
- 125000001424 substituent group Chemical group 0.000 claims abstract 4
- -1 alkylene radical Chemical class 0.000 claims description 81
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims description 32
- 150000003839 salts Chemical class 0.000 claims description 27
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims description 24
- 125000004432 carbon atom Chemical group C* 0.000 claims description 20
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 19
- 239000007858 starting material Substances 0.000 claims description 19
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 18
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 15
- 239000001257 hydrogen Substances 0.000 claims description 15
- 229910052739 hydrogen Inorganic materials 0.000 claims description 15
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 14
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 14
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 12
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 12
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 12
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 12
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 12
- NARVIWMVBMUEOG-UHFFFAOYSA-N 2-Hydroxy-propylene Natural products CC(O)=C NARVIWMVBMUEOG-UHFFFAOYSA-N 0.000 claims description 10
- 239000004480 active ingredient Substances 0.000 claims description 10
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 10
- 125000004193 piperazinyl group Chemical group 0.000 claims description 9
- 125000003386 piperidinyl group Chemical group 0.000 claims description 9
- 239000002904 solvent Substances 0.000 claims description 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
- 238000006243 chemical reaction Methods 0.000 claims description 8
- 238000009833 condensation Methods 0.000 claims description 8
- 230000005494 condensation Effects 0.000 claims description 8
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 8
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 claims description 8
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 8
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 7
- 229910052757 nitrogen Inorganic materials 0.000 claims description 7
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 7
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 125000002883 imidazolyl group Chemical group 0.000 claims description 6
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 5
- 150000001412 amines Chemical class 0.000 claims description 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 4
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical group [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 claims description 4
- 125000002947 alkylene group Chemical group 0.000 claims description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 4
- 125000005843 halogen group Chemical group 0.000 claims description 4
- 125000004076 pyridyl group Chemical group 0.000 claims description 4
- 150000003254 radicals Chemical class 0.000 claims description 4
- 208000011580 syndromic disease Diseases 0.000 claims description 4
- 239000002246 antineoplastic agent Substances 0.000 claims description 3
- 229940041181 antineoplastic drug Drugs 0.000 claims description 3
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- ITAMRBIZWGDOHW-UHFFFAOYSA-N fantofarone Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCOC1=CC=C(S(=O)(=O)C2=C3C=CC=CN3C=C2C(C)C)C=C1 ITAMRBIZWGDOHW-UHFFFAOYSA-N 0.000 claims description 3
- 150000007522 mineralic acids Chemical class 0.000 claims description 3
- 230000001575 pathological effect Effects 0.000 claims description 3
- 230000003389 potentiating effect Effects 0.000 claims description 3
- 239000012454 non-polar solvent Substances 0.000 claims description 2
- 150000007524 organic acids Chemical class 0.000 claims description 2
- 239000002798 polar solvent Substances 0.000 claims description 2
- 150000002431 hydrogen Chemical group 0.000 claims 6
- 125000002774 3,4-dimethoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C(OC([H])([H])[H])=C1OC([H])([H])[H])C([H])([H])* 0.000 claims 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims 4
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 3
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims 1
- PPBBSDANFIPZDM-UHFFFAOYSA-N 4-indolizin-1-ylsulfonylphenol Chemical compound C1=CC(O)=CC=C1S(=O)(=O)C1=C2C=CC=CN2C=C1 PPBBSDANFIPZDM-UHFFFAOYSA-N 0.000 claims 1
- 150000003840 hydrochlorides Chemical class 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 96
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 56
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 51
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 42
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 39
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 30
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 14
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 239000011575 calcium Substances 0.000 description 11
- 206010002383 Angina Pectoris Diseases 0.000 description 10
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 10
- 229910000027 potassium carbonate Inorganic materials 0.000 description 10
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 239000002876 beta blocker Substances 0.000 description 9
- 229910052791 calcium Inorganic materials 0.000 description 9
- 239000011541 reaction mixture Substances 0.000 description 9
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- 229940097320 beta blocking agent Drugs 0.000 description 8
- 230000008602 contraction Effects 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 229910052783 alkali metal Inorganic materials 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- FMAWAVRGYAKOGW-UHFFFAOYSA-N 4h-indolizin-4-ium;chloride Chemical compound Cl.C1=CC=CN2C=CC=C21 FMAWAVRGYAKOGW-UHFFFAOYSA-N 0.000 description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 6
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 6
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 6
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 6
- 150000008041 alkali metal carbonates Chemical class 0.000 description 6
- 230000001466 anti-adreneric effect Effects 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 229910052700 potassium Inorganic materials 0.000 description 6
- 239000011591 potassium Substances 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 239000000377 silicon dioxide Substances 0.000 description 6
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 5
- 150000001340 alkali metals Chemical class 0.000 description 5
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 5
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 5
- 230000002526 effect on cardiovascular system Effects 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 239000012074 organic phase Substances 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 230000033764 rhythmic process Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- CLQBBAMUAPQHRE-UHFFFAOYSA-N 1-[4-(3-bromopropoxy)phenyl]sulfonyl-2-ethylindolizine Chemical compound CCC1=CN2C=CC=CC2=C1S(=O)(=O)C1=CC=C(OCCCBr)C=C1 CLQBBAMUAPQHRE-UHFFFAOYSA-N 0.000 description 4
- XZVULSQFWZMGQV-UHFFFAOYSA-N 4-(2-propan-2-ylindolizin-1-yl)sulfonylphenol Chemical compound CC(C)C1=CN2C=CC=CC2=C1S(=O)(=O)C1=CC=C(O)C=C1 XZVULSQFWZMGQV-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000000480 calcium channel blocker Substances 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- JQVDAXLFBXTEQA-UHFFFAOYSA-N dibutylamine Chemical compound CCCCNCCCC JQVDAXLFBXTEQA-UHFFFAOYSA-N 0.000 description 4
- ZMXDDKWLCZADIW-UHFFFAOYSA-N dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 4
- 230000028161 membrane depolarization Effects 0.000 description 4
- WPISNXOKHKTTRN-UHFFFAOYSA-N n-butyl-n-[3-[4-(2-propan-2-ylindolizin-1-yl)sulfanylphenoxy]propyl]butan-1-amine;oxalic acid Chemical compound OC(=O)C(O)=O.C1=CC(OCCCN(CCCC)CCCC)=CC=C1SC1=C2C=CC=CN2C=C1C(C)C WPISNXOKHKTTRN-UHFFFAOYSA-N 0.000 description 4
- 239000003208 petroleum Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 3
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 3
- 229930182837 (R)-adrenaline Natural products 0.000 description 3
- VFYSNYOCGACPOA-UHFFFAOYSA-N 1-(dibutylamino)-3-[4-(2-propan-2-ylindolizin-1-yl)sulfonylphenoxy]propan-2-ol;hydrochloride Chemical compound Cl.C1=CC(OCC(O)CN(CCCC)CCCC)=CC=C1S(=O)(=O)C1=C2C=CC=CN2C=C1C(C)C VFYSNYOCGACPOA-UHFFFAOYSA-N 0.000 description 3
- TXRMLXWBMNETGN-UHFFFAOYSA-N 4-(2-propan-2-ylindolizin-1-yl)sulfanylphenol Chemical compound CC(C)C1=CN2C=CC=CC2=C1SC1=CC=C(O)C=C1 TXRMLXWBMNETGN-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- OSPBPWUJOZPDGM-UHFFFAOYSA-N [4-(2-propan-2-ylindolizin-1-yl)sulfonylphenyl] 4-methylbenzenesulfonate Chemical compound CC(C)C1=CN2C=CC=CC2=C1S(=O)(=O)C(C=C1)=CC=C1OS(=O)(=O)C1=CC=C(C)C=C1 OSPBPWUJOZPDGM-UHFFFAOYSA-N 0.000 description 3
- 229910000102 alkali metal hydride Inorganic materials 0.000 description 3
- 150000008046 alkali metal hydrides Chemical class 0.000 description 3
- 125000005278 alkyl sulfonyloxy group Chemical group 0.000 description 3
- 210000000709 aorta Anatomy 0.000 description 3
- 125000005279 aryl sulfonyloxy group Chemical group 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 230000001595 contractor effect Effects 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 229960005139 epinephrine Drugs 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 229960001317 isoprenaline Drugs 0.000 description 3
- BSARWJMYHLNELF-UHFFFAOYSA-N n-butyl-n-[3-[4-(2-ethylindolizin-1-yl)sulfonylphenoxy]propyl]butan-1-amine Chemical compound C1=CC(OCCCN(CCCC)CCCC)=CC=C1S(=O)(=O)C1=C2C=CC=CN2C=C1CC BSARWJMYHLNELF-UHFFFAOYSA-N 0.000 description 3
- 235000006408 oxalic acid Nutrition 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 description 2
- NNTPEAXKKUPBHQ-UHFFFAOYSA-N 1-bromo-3-methylbutan-2-one Chemical compound CC(C)C(=O)CBr NNTPEAXKKUPBHQ-UHFFFAOYSA-N 0.000 description 2
- LFOOXBDWIAJWHW-UHFFFAOYSA-N 2-ethyl-1-[4-(3-piperidin-1-ylpropoxy)phenyl]sulfonylindolizine;hydrochloride Chemical compound Cl.CCC1=CN2C=CC=CC2=C1S(=O)(=O)C(C=C1)=CC=C1OCCCN1CCCCC1 LFOOXBDWIAJWHW-UHFFFAOYSA-N 0.000 description 2
- LULAYUGMBFYYEX-UHFFFAOYSA-N 3-chlorobenzoic acid Chemical compound OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 description 2
- KTVOIVNDOVRIKP-UHFFFAOYSA-N 4-(2-ethylindolizin-1-yl)sulfonylphenol Chemical compound CCC1=CN2C=CC=CC2=C1S(=O)(=O)C1=CC=C(O)C=C1 KTVOIVNDOVRIKP-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 206010065929 Cardiovascular insufficiency Diseases 0.000 description 2
- 229940126062 Compound A Drugs 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 2
- 208000001871 Tachycardia Diseases 0.000 description 2
- NRTGWAAGLRTUJZ-UHFFFAOYSA-N [4-[3-(dibutylamino)propoxy]phenyl]-(2-ethylindolizin-3-yl)methanone Chemical compound C1=CC(OCCCN(CCCC)CCCC)=CC=C1C(=O)C1=C(CC)C=C2N1C=CC=C2 NRTGWAAGLRTUJZ-UHFFFAOYSA-N 0.000 description 2
- 230000001800 adrenalinergic effect Effects 0.000 description 2
- 239000000674 adrenergic antagonist Substances 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 230000006793 arrhythmia Effects 0.000 description 2
- 208000037849 arterial hypertension Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 229950007869 butoprozine Drugs 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- MOIPGXQKZSZOQX-UHFFFAOYSA-N carbonyl bromide Chemical compound BrC(Br)=O MOIPGXQKZSZOQX-UHFFFAOYSA-N 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 239000008119 colloidal silica Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 2
- 230000004118 muscle contraction Effects 0.000 description 2
- DIYJRPZSJBZLBX-UHFFFAOYSA-N n-[3-[4-(2-ethylindolizin-1-yl)sulfonylphenoxy]propyl]-2-methylpropan-2-amine;hydrochloride Chemical compound Cl.CCC1=CN2C=CC=CC2=C1S(=O)(=O)C1=CC=C(OCCCNC(C)(C)C)C=C1 DIYJRPZSJBZLBX-UHFFFAOYSA-N 0.000 description 2
- JSYKDQFGZZDDTI-UHFFFAOYSA-N n-butyl-n-[3-[4-(2-propan-2-ylindolizin-1-yl)sulfinylphenoxy]propyl]butan-1-amine;oxalic acid Chemical compound OC(=O)C(O)=O.C1=CC(OCCCN(CCCC)CCCC)=CC=C1S(=O)C1=C2C=CC=CN2C=C1C(C)C JSYKDQFGZZDDTI-UHFFFAOYSA-N 0.000 description 2
- OBSVCIXHMYVRAR-UHFFFAOYSA-N n-butyl-n-[3-[4-(2-propan-2-ylindolizin-1-yl)sulfonylphenoxy]propyl]butan-1-amine;oxalic acid Chemical compound OC(=O)C(O)=O.C1=CC(OCCCN(CCCC)CCCC)=CC=C1S(=O)(=O)C1=C2C=CC=CN2C=C1C(C)C OBSVCIXHMYVRAR-UHFFFAOYSA-N 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- BBFCIBZLAVOLCF-UHFFFAOYSA-N pyridin-1-ium;bromide Chemical compound Br.C1=CC=NC=C1 BBFCIBZLAVOLCF-UHFFFAOYSA-N 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000006794 tachycardia Effects 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- VEFLKXRACNJHOV-UHFFFAOYSA-N 1,3-dibromopropane Chemical compound BrCCCBr VEFLKXRACNJHOV-UHFFFAOYSA-N 0.000 description 1
- QYBICPAYUFCUKS-UHFFFAOYSA-N 1-[2-[(4-hydroxyphenyl)sulfanylmethyl]pyridin-1-ium-1-yl]-3-methylbutan-2-one;bromide Chemical compound [Br-].CC(C)C(=O)C[N+]1=CC=CC=C1CSC1=CC=C(O)C=C1 QYBICPAYUFCUKS-UHFFFAOYSA-N 0.000 description 1
- WLROFHCPGCUWMT-UHFFFAOYSA-N 1-[4-(2-bromoethoxy)phenyl]sulfonyl-2-ethylindolizine Chemical compound CCC1=CN2C=CC=CC2=C1S(=O)(=O)C1=CC=C(OCCBr)C=C1 WLROFHCPGCUWMT-UHFFFAOYSA-N 0.000 description 1
- UGOZBYOTKCMJCI-UHFFFAOYSA-N 1-[4-(3-bromopropoxy)-3-methylphenyl]sulfonyl-2-phenylindolizine Chemical compound C1=C(OCCCBr)C(C)=CC(S(=O)(=O)C2=C3C=CC=CN3C=C2C=2C=CC=CC=2)=C1 UGOZBYOTKCMJCI-UHFFFAOYSA-N 0.000 description 1
- HBOGIXJDFIEUCC-UHFFFAOYSA-N 1-[4-(3-bromopropoxy)phenyl]sulfonyl-2-butylindolizine Chemical compound CCCCC1=CN2C=CC=CC2=C1S(=O)(=O)C1=CC=C(OCCCBr)C=C1 HBOGIXJDFIEUCC-UHFFFAOYSA-N 0.000 description 1
- PTWQUUAELFDAQQ-UHFFFAOYSA-N 1-[4-(3-bromopropoxy)phenyl]sulfonyl-2-phenylindolizine Chemical compound C1=CC(OCCCBr)=CC=C1S(=O)(=O)C1=C2C=CC=CN2C=C1C1=CC=CC=C1 PTWQUUAELFDAQQ-UHFFFAOYSA-N 0.000 description 1
- WUQOGFXYLYDTJO-UHFFFAOYSA-N 1-[4-(3-bromopropoxy)phenyl]sulfonyl-2-propan-2-ylindolizine Chemical compound CC(C)C1=CN2C=CC=CC2=C1S(=O)(=O)C1=CC=C(OCCCBr)C=C1 WUQOGFXYLYDTJO-UHFFFAOYSA-N 0.000 description 1
- LUKFPHPWEULOLE-UHFFFAOYSA-N 1-[4-(4-bromobutoxy)phenyl]sulfonyl-2-ethylindolizine Chemical compound CCC1=CN2C=CC=CC2=C1S(=O)(=O)C1=CC=C(OCCCCBr)C=C1 LUKFPHPWEULOLE-UHFFFAOYSA-N 0.000 description 1
- MAWBUVTWCGXIQY-UHFFFAOYSA-N 1-[4-(4-bromobutoxy)phenyl]sulfonyl-2-propan-2-ylindolizine Chemical compound CC(C)C1=CN2C=CC=CC2=C1S(=O)(=O)C1=CC=C(OCCCCBr)C=C1 MAWBUVTWCGXIQY-UHFFFAOYSA-N 0.000 description 1
- FTGDSIXTSCZOOY-UHFFFAOYSA-N 1-[4-[3-(4-benzhydrylpiperazin-1-yl)propoxy]phenyl]sulfonyl-2-propan-2-ylindolizine Chemical compound CC(C)C1=CN2C=CC=CC2=C1S(=O)(=O)C(C=C1)=CC=C1OCCCN(CC1)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 FTGDSIXTSCZOOY-UHFFFAOYSA-N 0.000 description 1
- FEGCNBPKWNAYBR-UHFFFAOYSA-N 1-[4-[3-(4-phenylpiperidin-1-yl)propoxy]phenyl]sulfonyl-2-propan-2-ylindolizine Chemical compound CC(C)C1=CN2C=CC=CC2=C1S(=O)(=O)C(C=C1)=CC=C1OCCCN(CC1)CCC1C1=CC=CC=C1 FEGCNBPKWNAYBR-UHFFFAOYSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- BGEONUMCBIQUTQ-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-n-methylethanamine;hydron;chloride Chemical compound Cl.CNCCC1=CC=C(OC)C(OC)=C1 BGEONUMCBIQUTQ-UHFFFAOYSA-N 0.000 description 1
- NJWIMFZLESWFIM-UHFFFAOYSA-N 2-(chloromethyl)pyridine Chemical compound ClCC1=CC=CC=N1 NJWIMFZLESWFIM-UHFFFAOYSA-N 0.000 description 1
- LWZGWUUNGDPBLZ-UHFFFAOYSA-N 2-ethyl-1-[4-(3-imidazol-1-ylpropoxy)phenyl]sulfonylindolizine Chemical compound CCC1=CN2C=CC=CC2=C1S(=O)(=O)C(C=C1)=CC=C1OCCCN1C=CN=C1 LWZGWUUNGDPBLZ-UHFFFAOYSA-N 0.000 description 1
- DSFPNAVTQXWXAN-UHFFFAOYSA-N 2-methyl-n-[3-[2-methyl-4-(2-phenylindolizin-1-yl)sulfonylphenoxy]propyl]propan-2-amine;hydrochloride Chemical compound Cl.C1=C(OCCCNC(C)(C)C)C(C)=CC(S(=O)(=O)C2=C3C=CC=CN3C=C2C=2C=CC=CC=2)=C1 DSFPNAVTQXWXAN-UHFFFAOYSA-N 0.000 description 1
- IARBDKXEKHCPJK-UHFFFAOYSA-N 2-methyl-n-[3-[4-(2-phenylindolizin-1-yl)sulfonylphenoxy]propyl]propan-2-amine;hydrochloride Chemical compound Cl.C1=CC(OCCCNC(C)(C)C)=CC=C1S(=O)(=O)C1=C2C=CC=CN2C=C1C1=CC=CC=C1 IARBDKXEKHCPJK-UHFFFAOYSA-N 0.000 description 1
- NKTNZCIEQGDMGY-UHFFFAOYSA-N 3,4-dimethoxy-n-[3-[4-(2-propan-2-ylindolizin-1-yl)sulfonylphenoxy]propyl]aniline;hydrochloride Chemical compound Cl.C1=C(OC)C(OC)=CC=C1NCCCOC1=CC=C(S(=O)(=O)C2=C3C=CC=CN3C=C2C(C)C)C=C1 NKTNZCIEQGDMGY-UHFFFAOYSA-N 0.000 description 1
- UBVTWDNKBINAIQ-UHFFFAOYSA-N 3-[4-(2-butylindolizin-1-yl)sulfonylphenoxy]-n,n-dipropylpropan-1-amine;oxalic acid Chemical compound OC(=O)C(O)=O.CCCCC1=CN2C=CC=CC2=C1S(=O)(=O)C1=CC=C(OCCCN(CCC)CCC)C=C1 UBVTWDNKBINAIQ-UHFFFAOYSA-N 0.000 description 1
- XAVNCHWFUHRVGN-UHFFFAOYSA-N 4-(2-butylindolizin-1-yl)sulfonylphenol Chemical compound CCCCC1=CN2C=CC=CC2=C1S(=O)(=O)C1=CC=C(O)C=C1 XAVNCHWFUHRVGN-UHFFFAOYSA-N 0.000 description 1
- BUDZNYHOONIUJB-UHFFFAOYSA-N 4-(2-cyclohexylindolizin-1-yl)sulfonylphenol Chemical compound C1=CC(O)=CC=C1S(=O)(=O)C1=C2C=CC=CN2C=C1C1CCCCC1 BUDZNYHOONIUJB-UHFFFAOYSA-N 0.000 description 1
- WVLFERSIPLANAJ-UHFFFAOYSA-N 4-(2-ethylindolizin-1-yl)sulfonyl-2,6-dimethylphenol Chemical compound CCC1=CN2C=CC=CC2=C1S(=O)(=O)C1=CC(C)=C(O)C(C)=C1 WVLFERSIPLANAJ-UHFFFAOYSA-N 0.000 description 1
- UGWBYNPFXNSKMO-UHFFFAOYSA-N 4-(2-ethylindolizin-1-yl)sulfonyl-2-methylphenol Chemical compound CCC1=CN2C=CC=CC2=C1S(=O)(=O)C1=CC=C(O)C(C)=C1 UGWBYNPFXNSKMO-UHFFFAOYSA-N 0.000 description 1
- KMDZTAOQVHHJAH-UHFFFAOYSA-N 4-(2-methylindolizin-1-yl)sulfonylphenol Chemical compound CC1=CN2C=CC=CC2=C1S(=O)(=O)C1=CC=C(O)C=C1 KMDZTAOQVHHJAH-UHFFFAOYSA-N 0.000 description 1
- JPICGCBLGAVKBT-UHFFFAOYSA-N 4-(2-phenylindolizin-1-yl)sulfonylphenol Chemical compound C1=CC(O)=CC=C1S(=O)(=O)C1=C2C=CC=CN2C=C1C1=CC=CC=C1 JPICGCBLGAVKBT-UHFFFAOYSA-N 0.000 description 1
- QKCJDTNEJQFXLC-UHFFFAOYSA-N 4-(2-propylindolizin-1-yl)sulfonylphenol Chemical compound CCCC1=CN2C=CC=CC2=C1S(=O)(=O)C1=CC=C(O)C=C1 QKCJDTNEJQFXLC-UHFFFAOYSA-N 0.000 description 1
- SLDADUYVXBINQR-UHFFFAOYSA-N 4-(2-tert-butylindolizin-1-yl)sulfonylphenol Chemical compound CC(C)(C)C1=CN2C=CC=CC2=C1S(=O)(=O)C1=CC=C(O)C=C1 SLDADUYVXBINQR-UHFFFAOYSA-N 0.000 description 1
- DMDUUPQDOLAGHF-UHFFFAOYSA-N 4-(pyridin-2-ylmethylsulfanyl)phenol Chemical compound C1=CC(O)=CC=C1SCC1=CC=CC=N1 DMDUUPQDOLAGHF-UHFFFAOYSA-N 0.000 description 1
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- WDYVUKGVKRZQNM-UHFFFAOYSA-N 6-phosphonohexylphosphonic acid Chemical compound OP(O)(=O)CCCCCCP(O)(O)=O WDYVUKGVKRZQNM-UHFFFAOYSA-N 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- 206010002388 Angina unstable Diseases 0.000 description 1
- 206010003225 Arteriospasm coronary Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- SIGHKWWTZOUJBK-UHFFFAOYSA-N C(C(=O)O)(=O)O.C=1C=CN2C=CC=CC12 Chemical compound C(C(=O)O)(=O)O.C=1C=CN2C=CC=CC12 SIGHKWWTZOUJBK-UHFFFAOYSA-N 0.000 description 1
- GQHTXRPLIQLUHW-UHFFFAOYSA-N CC1=CC=C(C=C1)S(=O)(=O)OC2=CC=C(C=C2)C3=C(C=CC=N3)CS(=O)(=O)CC4=C(N=CC=C4)C5=CC=C(C=C5)OS(=O)(=O)C6=CC=C(C=C6)C Chemical compound CC1=CC=C(C=C1)S(=O)(=O)OC2=CC=C(C=C2)C3=C(C=CC=N3)CS(=O)(=O)CC4=C(N=CC=C4)C5=CC=C(C=C5)OS(=O)(=O)C6=CC=C(C=C6)C GQHTXRPLIQLUHW-UHFFFAOYSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- PWBSHRUAJBEENP-UHFFFAOYSA-N Cl.C1=C(C)C(OCCCN(CCCC)CCCC)=CC=C1S(=O)(=O)C1=C2C=CC=CN2C=C1C1=CC=CC=C1 Chemical compound Cl.C1=C(C)C(OCCCN(CCCC)CCCC)=CC=C1S(=O)(=O)C1=C2C=CC=CN2C=C1C1=CC=CC=C1 PWBSHRUAJBEENP-UHFFFAOYSA-N 0.000 description 1
- 208000003890 Coronary Vasospasm Diseases 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000220225 Malus Species 0.000 description 1
- 235000011430 Malus pumila Nutrition 0.000 description 1
- 235000015103 Malus silvestris Nutrition 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- HNJWKRMESUMDQE-UHFFFAOYSA-N N-methylhomoveratrylamine hydrochloride Natural products CNCCC1=CC=C(OC)C(OC)=C1 HNJWKRMESUMDQE-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000906446 Theraps Species 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- DWDABYAPJKJJEM-UHFFFAOYSA-N [4-(2-butylindolizin-1-yl)sulfonylphenyl] 4-methylbenzenesulfonate Chemical compound CCCCC1=CN2C=CC=CC2=C1S(=O)(=O)C(C=C1)=CC=C1OS(=O)(=O)C1=CC=C(C)C=C1 DWDABYAPJKJJEM-UHFFFAOYSA-N 0.000 description 1
- FCCHXNNQQZAKDI-UHFFFAOYSA-N [4-(2-cyclohexylindolizin-1-yl)sulfonylphenyl] 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OC1=CC=C(S(=O)(=O)C2=C3C=CC=CN3C=C2C2CCCCC2)C=C1 FCCHXNNQQZAKDI-UHFFFAOYSA-N 0.000 description 1
- NBUZEAHIZKEKTI-UHFFFAOYSA-N [4-(2-ethylindolizin-1-yl)sulfonyl-2-methylphenyl] 4-methylbenzenesulfonate Chemical compound CCC1=CN2C=CC=CC2=C1S(=O)(=O)C(C=C1C)=CC=C1OS(=O)(=O)C1=CC=C(C)C=C1 NBUZEAHIZKEKTI-UHFFFAOYSA-N 0.000 description 1
- KOLFSZDWUMYECJ-UHFFFAOYSA-N [4-(2-ethylindolizin-1-yl)sulfonylphenyl] 4-methylbenzenesulfonate Chemical compound CCC1=CN2C=CC=CC2=C1S(=O)(=O)C(C=C1)=CC=C1OS(=O)(=O)C1=CC=C(C)C=C1 KOLFSZDWUMYECJ-UHFFFAOYSA-N 0.000 description 1
- HOJJIOWANOQFTN-UHFFFAOYSA-N [4-(2-methylindolizin-1-yl)sulfonylphenyl] 4-methylbenzenesulfonate Chemical compound CC1=CN2C=CC=CC2=C1S(=O)(=O)C(C=C1)=CC=C1OS(=O)(=O)C1=CC=C(C)C=C1 HOJJIOWANOQFTN-UHFFFAOYSA-N 0.000 description 1
- LXEGQSDIQOZITL-UHFFFAOYSA-N [4-(2-phenylindolizin-1-yl)sulfonylphenyl] 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OC1=CC=C(S(=O)(=O)C2=C3C=CC=CN3C=C2C=2C=CC=CC=2)C=C1 LXEGQSDIQOZITL-UHFFFAOYSA-N 0.000 description 1
- UQOWVOJXGGTKIV-UHFFFAOYSA-N [4-(2-propylindolizin-1-yl)sulfonylphenyl] 4-methylbenzenesulfonate Chemical compound CCCC1=CN2C=CC=CC2=C1S(=O)(=O)C(C=C1)=CC=C1OS(=O)(=O)C1=CC=C(C)C=C1 UQOWVOJXGGTKIV-UHFFFAOYSA-N 0.000 description 1
- UULBGISPCCMKAJ-UHFFFAOYSA-N [4-(2-tert-butylindolizin-1-yl)sulfonylphenyl] 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OC1=CC=C(S(=O)(=O)C2=C3C=CC=CN3C=C2C(C)(C)C)C=C1 UULBGISPCCMKAJ-UHFFFAOYSA-N 0.000 description 1
- MAZGPSPJQFPJCX-UHFFFAOYSA-N [4-[3-(dibutylamino)propoxy]phenyl]-(2-ethylindolizin-1-yl)methanone Chemical compound C1=CC(OCCCN(CCCC)CCCC)=CC=C1C(=O)C1=C2C=CC=CN2C=C1CC MAZGPSPJQFPJCX-UHFFFAOYSA-N 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000036982 action potential Effects 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910001854 alkali hydroxide Inorganic materials 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- 239000002160 alpha blocker Substances 0.000 description 1
- 229940124308 alpha-adrenoreceptor antagonist Drugs 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- JEHKKBHWRAXMCH-UHFFFAOYSA-M benzenesulfinate Chemical compound [O-]S(=O)C1=CC=CC=C1 JEHKKBHWRAXMCH-UHFFFAOYSA-M 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- SIKJAQJRHWYJAI-UHFFFAOYSA-N benzopyrrole Natural products C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 230000000059 bradycardiac effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 230000005792 cardiovascular activity Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- ZJYAYOPCVZDLEP-UHFFFAOYSA-N chloroform methanol Chemical compound OC.OC.ClC(Cl)Cl.ClC(Cl)Cl ZJYAYOPCVZDLEP-UHFFFAOYSA-N 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 201000011634 coronary artery vasospasm Diseases 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
- 229960004166 diltiazem Drugs 0.000 description 1
- 238000009429 electrical wiring Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000001435 haemodynamic effect Effects 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical group 0.000 description 1
- 210000002064 heart cell Anatomy 0.000 description 1
- 230000010247 heart contraction Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 125000005948 methanesulfonyloxy group Chemical group 0.000 description 1
- FZFLBSCDHWFWGS-UHFFFAOYSA-N n,n-dibutyl-4-[4-(2-ethylindolizin-1-yl)sulfonylphenoxy]butan-1-amine Chemical compound C1=CC(OCCCCN(CCCC)CCCC)=CC=C1S(=O)(=O)C1=C2C=CC=CN2C=C1CC FZFLBSCDHWFWGS-UHFFFAOYSA-N 0.000 description 1
- CQNMHMMHPKRUNG-UHFFFAOYSA-N n,n-diethyl-3-[4-(2-methylindolizin-1-yl)sulfonylphenoxy]propan-1-amine;oxalic acid Chemical compound OC(=O)C(O)=O.C1=CC(OCCCN(CC)CC)=CC=C1S(=O)(=O)C1=C2C=CC=CN2C=C1C CQNMHMMHPKRUNG-UHFFFAOYSA-N 0.000 description 1
- ZOVYEGQWXPIAQZ-UHFFFAOYSA-N n,n-diethyl-3-[4-(2-propan-2-ylindolizin-1-yl)sulfonylphenoxy]propan-1-amine Chemical compound C1=CC(OCCCN(CC)CC)=CC=C1S(=O)(=O)C1=C2C=CC=CN2C=C1C(C)C ZOVYEGQWXPIAQZ-UHFFFAOYSA-N 0.000 description 1
- SPMWKTGMLCBABN-UHFFFAOYSA-N n,n-dimethyl-3-[4-(2-propan-2-ylindolizin-1-yl)sulfonylphenoxy]propan-1-amine Chemical compound CC(C)C1=CN2C=CC=CC2=C1S(=O)(=O)C1=CC=C(OCCCN(C)C)C=C1 SPMWKTGMLCBABN-UHFFFAOYSA-N 0.000 description 1
- NIOVWDWNPNKWSM-UHFFFAOYSA-N n-[(3,4-dimethoxyphenyl)methyl]-3-[4-(2-propan-2-ylindolizin-1-yl)sulfonylphenoxy]propan-1-amine Chemical compound C1=C(OC)C(OC)=CC=C1CNCCCOC1=CC=C(S(=O)(=O)C2=C3C=CC=CN3C=C2C(C)C)C=C1 NIOVWDWNPNKWSM-UHFFFAOYSA-N 0.000 description 1
- YLUXAMLYZDMVCY-UHFFFAOYSA-N n-[3-[4-(2-butylindolizin-1-yl)sulfonylphenoxy]propyl]-2-methylpropan-2-amine;oxalic acid Chemical compound OC(=O)C(O)=O.CCCCC1=CN2C=CC=CC2=C1S(=O)(=O)C1=CC=C(OCCCNC(C)(C)C)C=C1 YLUXAMLYZDMVCY-UHFFFAOYSA-N 0.000 description 1
- YXZFQUGXVBSNKO-UHFFFAOYSA-N n-[3-[4-(2-ethylindolizin-1-yl)sulfonylphenoxy]propyl]-n-pentylpentan-1-amine;hydrochloride Chemical compound Cl.C1=CC(OCCCN(CCCCC)CCCCC)=CC=C1S(=O)(=O)C1=C2C=CC=CN2C=C1CC YXZFQUGXVBSNKO-UHFFFAOYSA-N 0.000 description 1
- DHWCWEDHJPXCEI-UHFFFAOYSA-N n-[3-[4-(2-ethylindolizin-1-yl)sulfonylphenoxy]propyl]butan-1-amine;oxalic acid Chemical compound OC(=O)C(O)=O.C1=CC(OCCCNCCCC)=CC=C1S(=O)(=O)C1=C2C=CC=CN2C=C1CC DHWCWEDHJPXCEI-UHFFFAOYSA-N 0.000 description 1
- YHHYKRDPFYEQBI-UHFFFAOYSA-N n-butyl-n-(1-chloropropyl)butan-1-amine Chemical compound CCCCN(C(Cl)CC)CCCC YHHYKRDPFYEQBI-UHFFFAOYSA-N 0.000 description 1
- ANLMKUQEPXRMGV-UHFFFAOYSA-N n-butyl-n-(3-chloropropyl)butan-1-amine Chemical compound CCCCN(CCCC)CCCCl ANLMKUQEPXRMGV-UHFFFAOYSA-N 0.000 description 1
- QHFXZRABQDVSGU-UHFFFAOYSA-N n-butyl-n-[2-[4-(2-ethylindolizin-1-yl)sulfonylphenoxy]ethyl]butan-1-amine;hydrochloride Chemical compound Cl.C1=CC(OCCN(CCCC)CCCC)=CC=C1S(=O)(=O)C1=C2C=CC=CN2C=C1CC QHFXZRABQDVSGU-UHFFFAOYSA-N 0.000 description 1
- ZMCFCRILKPWYKC-UHFFFAOYSA-N n-butyl-n-[3-[4-(2-butylindolizin-1-yl)sulfonylphenoxy]propyl]butan-1-amine;oxalic acid Chemical compound OC(=O)C(O)=O.C1=CC(OCCCN(CCCC)CCCC)=CC=C1S(=O)(=O)C1=C2C=CC=CN2C=C1CCCC ZMCFCRILKPWYKC-UHFFFAOYSA-N 0.000 description 1
- DNVSHEVUODCBND-UHFFFAOYSA-N n-butyl-n-[3-[4-(2-cyclohexylindolizin-1-yl)sulfonylphenoxy]propyl]butan-1-amine Chemical compound C1=CC(OCCCN(CCCC)CCCC)=CC=C1S(=O)(=O)C1=C2C=CC=CN2C=C1C1CCCCC1 DNVSHEVUODCBND-UHFFFAOYSA-N 0.000 description 1
- BMPYCJDRVDHEQG-UHFFFAOYSA-N n-butyl-n-[3-[4-(2-methylindolizin-1-yl)sulfonylphenoxy]propyl]butan-1-amine;oxalic acid Chemical compound OC(=O)C(O)=O.C1=CC(OCCCN(CCCC)CCCC)=CC=C1S(=O)(=O)C1=C2C=CC=CN2C=C1C BMPYCJDRVDHEQG-UHFFFAOYSA-N 0.000 description 1
- QDJGWAVLPUZHNP-UHFFFAOYSA-N n-butyl-n-[3-[4-(2-phenylindolizin-1-yl)sulfonylphenoxy]propyl]butan-1-amine;hydrochloride Chemical compound Cl.C1=CC(OCCCN(CCCC)CCCC)=CC=C1S(=O)(=O)C1=C2C=CC=CN2C=C1C1=CC=CC=C1 QDJGWAVLPUZHNP-UHFFFAOYSA-N 0.000 description 1
- MLVJLNHTLWGDOJ-UHFFFAOYSA-N n-butyl-n-[3-[4-(2-tert-butylindolizin-1-yl)sulfonylphenoxy]propyl]butan-1-amine Chemical compound C1=CC(OCCCN(CCCC)CCCC)=CC=C1S(=O)(=O)C1=C2C=CC=CN2C=C1C(C)(C)C MLVJLNHTLWGDOJ-UHFFFAOYSA-N 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- BZMMCTGMVBTMHH-UHFFFAOYSA-N oxalic acid;3-[4-(2-propan-2-ylindolizin-1-yl)sulfonylphenoxy]-n,n-dipropylpropan-1-amine Chemical compound OC(=O)C(O)=O.C1=CC(OCCCN(CCC)CCC)=CC=C1S(=O)(=O)C1=C2C=CC=CN2C=C1C(C)C BZMMCTGMVBTMHH-UHFFFAOYSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 239000012057 packaged powder Substances 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 125000004115 pentoxy group Chemical group [*]OC([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 230000016160 smooth muscle contraction Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000036977 tonic contraction Effects 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8602045A FR2594438B1 (fr) | 1986-02-14 | 1986-02-14 | Derives d'indolizine, leur procede de preparation ainsi que les compositions en contenant |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SK97787A3 SK97787A3 (en) | 1998-12-02 |
| SK279557B6 true SK279557B6 (sk) | 1998-12-02 |
Family
ID=9332147
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK977-87A SK279557B6 (sk) | 1986-02-14 | 1987-02-13 | Deriváty indolizínu, spôsob ich prípravy a farmace |
Country Status (33)
| Country | Link |
|---|---|
| US (5) | US4957925A (cs) |
| EP (1) | EP0235111B1 (cs) |
| JP (1) | JP2547004B2 (cs) |
| KR (1) | KR870007931A (cs) |
| AR (1) | AR245127A1 (cs) |
| AT (1) | ATE62485T1 (cs) |
| AU (1) | AU587525B2 (cs) |
| BE (1) | BE1006666A4 (cs) |
| CA (1) | CA1310965C (cs) |
| CZ (1) | CZ281209B6 (cs) |
| DD (1) | DD264436A5 (cs) |
| DE (1) | DE3769174D1 (cs) |
| DK (1) | DK170403B1 (cs) |
| ES (1) | ES2040276T3 (cs) |
| FI (1) | FI84353C (cs) |
| FR (1) | FR2594438B1 (cs) |
| GR (1) | GR3001883T3 (cs) |
| HU (1) | HU196401B (cs) |
| IE (1) | IE59656B1 (cs) |
| IL (1) | IL81358A (cs) |
| MA (1) | MA20878A1 (cs) |
| MY (1) | MY101541A (cs) |
| NO (1) | NO165344C (cs) |
| NZ (1) | NZ219274A (cs) |
| OA (1) | OA08481A (cs) |
| PH (1) | PH24830A (cs) |
| PL (2) | PL152609B1 (cs) |
| PT (1) | PT84277B (cs) |
| SK (1) | SK279557B6 (cs) |
| SU (2) | SU1486064A3 (cs) |
| TN (1) | TNSN87021A1 (cs) |
| YU (2) | YU21287A (cs) |
| ZA (1) | ZA87471B (cs) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2594438B1 (fr) * | 1986-02-14 | 1990-01-26 | Labaz Sanofi Nv | Derives d'indolizine, leur procede de preparation ainsi que les compositions en contenant |
| US5215988A (en) * | 1986-02-14 | 1993-06-01 | Sanofi | Aminoalkoxyphenyl derivatives, process of preparation and compositions containing the same |
| US5182291A (en) * | 1986-02-14 | 1993-01-26 | Sanofi | Pyrozala-pyridyl aminoabkoxyphenol compounds |
| IL87181A (en) * | 1987-08-07 | 1993-08-18 | Sanofi Sa | Aminoalkoxyphenyl derivatives, their preparation and pharmaceutical and veterinary compositions containing them |
| IT1224404B (it) | 1987-12-23 | 1990-10-04 | Simes | Composti attivi sul sistema cardiovascolare |
| FR2633622B1 (fr) * | 1988-07-04 | 1991-05-17 | Sanofi Sa | Derives de sulfonyl indolizine, leur procede de preparation et leur utilisation comme intermediaires de synthese |
| CA2008985A1 (en) * | 1989-02-06 | 1990-08-06 | Jean Gubin | Aminoalkoxyphenyl derivatives, process of preparation and compositions containing the same |
| FR2642756B1 (fr) * | 1989-02-07 | 1994-03-04 | Sanofi | Derives cycloaminoalkoxyphenyle, leur procede de preparation ainsi que les compositions pharmaceutiques ou veterinaires en contenant |
| FR2642755B1 (cs) * | 1989-02-07 | 1993-11-05 | Sanofi | |
| JPH07103105B2 (ja) * | 1989-05-12 | 1995-11-08 | 杏林製薬株式会社 | インドール誘導体及びその製造方法 |
| FR2665444B1 (fr) * | 1990-08-06 | 1992-11-27 | Sanofi Sa | Derives d'amino-benzofuranne, benzothiophene ou indole, leur procede de preparation ainsi que les compositions les contenant. |
| US5118707A (en) * | 1990-10-31 | 1992-06-02 | The Procter & Gamble Company | Compositions for regulating skin wrinkles comprising a benzofuran derivative |
| US5435991A (en) * | 1991-08-09 | 1995-07-25 | Nycomed Innovation Ab | Use of persistent heterocyclic free-radicals in magnetic resonance imaging |
| FR2692578B1 (fr) * | 1992-06-23 | 1995-06-30 | Sanofi Elf | Derives d'indolizines, procede de preparation et utilisation pour la preparation de composes aminoalkoxybenzenesulfonyl-indolizines a activite pharmaceutique. |
| FR2692574B1 (fr) * | 1992-06-23 | 1995-06-23 | Sanofi Elf | Derives hydroxy-4 benzenethio, leur preparation ainsi que leur utilisation pour la preparation de derives aminoalkoxybenzenesulfonyles. |
| US5922773A (en) * | 1992-12-04 | 1999-07-13 | The Children's Medical Center Corp. | Glaucoma treatment |
| FR2725133B1 (fr) * | 1994-09-30 | 1996-12-20 | Sanofi Sa | Composition pharmaceutique de fantofarone pour administration orale |
| EP0888310B1 (en) | 1996-03-15 | 2005-09-07 | AstraZeneca AB | Cinnoline derivatives and use as medicine |
| US6482854B1 (en) | 1999-03-25 | 2002-11-19 | Massachusetts Eye And Ear Infirmary | Glaucoma treatment |
| TWI312347B (en) | 2001-02-08 | 2009-07-21 | Eisai R&D Man Co Ltd | Bicyclic nitrogen-containing condensed ring compounds |
| AU2002314744A1 (en) * | 2001-04-17 | 2002-10-28 | Sepracor, Inc. | Thiazole and other heterocyclic ligands and use thereof |
| US7091215B2 (en) * | 2001-04-27 | 2006-08-15 | Eisai Co., Ltd. | Pyrazolo[1,5-a]pyridines and medicines containing the same |
| FR2838123B1 (fr) * | 2002-04-04 | 2005-06-10 | Sanofi Synthelabo | Nouveaux derives d'indolozine-1,2,3 substituee, inhibiteurs selectifs du b-fgf |
| EP1554260A1 (en) * | 2002-10-22 | 2005-07-20 | Glaxo Group Limited | Aryloxyalkylamine derivatives as h3 receptor ligands |
| WO2004067540A1 (ja) * | 2003-01-31 | 2004-08-12 | Nippon Soda Co., Ltd. | 光変換性有機薄膜を形成する新規化合物および有機薄膜形成体 |
| CA2536912C (en) | 2003-08-27 | 2015-03-31 | Eyetech Pharmaceuticals, Inc. | Combination therapy for the treatment of ocular neovascular disorders |
| US20060141049A1 (en) * | 2003-11-12 | 2006-06-29 | Allergan, Inc. | Triamcinolone compositions for intravitreal administration to treat ocular conditions |
| US20070224278A1 (en) * | 2003-11-12 | 2007-09-27 | Lyons Robert T | Low immunogenicity corticosteroid compositions |
| US20050101582A1 (en) | 2003-11-12 | 2005-05-12 | Allergan, Inc. | Compositions and methods for treating a posterior segment of an eye |
| ATE418325T1 (de) | 2004-01-20 | 2009-01-15 | Allergan Inc | Zusammensetzungen für die lokalisierte therapie des auges, vorzugsweise enthaltend triamcinolon- acetonid und hyaluronsäure |
| US7993634B2 (en) | 2004-04-30 | 2011-08-09 | Allergan, Inc. | Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods |
| US20050244478A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Anti-excititoxic sustained release intraocular implants and related methods |
| US7799336B2 (en) | 2004-04-30 | 2010-09-21 | Allergan, Inc. | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
| US20050244465A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Drug delivery systems and methods for treatment of an eye |
| US20070059336A1 (en) * | 2004-04-30 | 2007-03-15 | Allergan, Inc. | Anti-angiogenic sustained release intraocular implants and related methods |
| US20050244472A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Intraocular drug delivery systems containing excipients with reduced toxicity and related methods |
| US8455656B2 (en) | 2004-04-30 | 2013-06-04 | Allergan, Inc. | Kinase inhibitors |
| US20050244463A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular vasculopathies |
| US8425929B2 (en) * | 2004-04-30 | 2013-04-23 | Allergan, Inc. | Sustained release intraocular implants and methods for preventing retinal dysfunction |
| US7771742B2 (en) | 2004-04-30 | 2010-08-10 | Allergan, Inc. | Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods |
| US20050244461A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Controlled release drug delivery systems and methods for treatment of an eye |
| US20050244466A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Photodynamic therapy in conjunction with intraocular implants |
| US20050244462A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Devices and methods for treating a mammalian eye |
| US8119154B2 (en) | 2004-04-30 | 2012-02-21 | Allergan, Inc. | Sustained release intraocular implants and related methods |
| US8722097B2 (en) | 2004-04-30 | 2014-05-13 | Allergan, Inc. | Oil-in-water method for making polymeric implants containing a hypotensive lipid |
| US20050244458A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular neuropathies |
| US20050244471A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Estradiol derivative and estratopone containing sustained release intraocular implants and related methods |
| US9498457B2 (en) | 2004-04-30 | 2016-11-22 | Allergan, Inc. | Hypotensive prostamide-containing biodegradable intraocular implants and related implants |
| US8591885B2 (en) * | 2004-04-30 | 2013-11-26 | Allergan, Inc. | Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems |
| WO2005107708A1 (en) | 2004-04-30 | 2005-11-17 | Allergan, Inc. | Biodegradable intravitreal tyrosine kinase inhibitors implants |
| US8147865B2 (en) * | 2004-04-30 | 2012-04-03 | Allergan, Inc. | Steroid-containing sustained release intraocular implants and related methods |
| US8673341B2 (en) * | 2004-04-30 | 2014-03-18 | Allergan, Inc. | Intraocular pressure reduction with intracameral bimatoprost implants |
| JP2008505978A (ja) * | 2004-07-12 | 2008-02-28 | アラーガン、インコーポレイテッド | 眼病用組成物および眼病治療法 |
| WO2006043965A1 (en) * | 2004-10-14 | 2006-04-27 | Allergan, Inc. | Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods |
| US20070293456A9 (en) * | 2004-12-30 | 2007-12-20 | Anthony Hayford | Method for the synthesis of 3-substituted indolizine and benzoindolizine compounds |
| CA2644240A1 (en) * | 2006-03-01 | 2007-09-13 | Roskamp Research, Llc | Compounds for inhibiting beta-amyloid production |
| US8969415B2 (en) | 2006-12-01 | 2015-03-03 | Allergan, Inc. | Intraocular drug delivery systems |
| US20100119599A1 (en) * | 2006-12-08 | 2010-05-13 | Archer Pharmaceuticals, Inc. | Polyhydroquinoline compounds and dihydropyridine compounds for inhibiting beta-amyloid production |
| US7911053B2 (en) * | 2007-04-19 | 2011-03-22 | Marvell World Trade Ltd. | Semiconductor packaging with internal wiring bus |
| SI2266990T1 (sl) * | 2008-04-15 | 2013-01-31 | Eisai R&D Management Co. Ltd. | Spojina 3-fenilpirazolo(5,1-b)tiazola |
| AR078521A1 (es) * | 2009-10-08 | 2011-11-16 | Eisai R&D Man Co Ltd | Compuesto pirazolotiazol |
| WO2011043387A1 (ja) * | 2009-10-08 | 2011-04-14 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ピラゾロオキサゾール化合物 |
| PL2498783T3 (pl) | 2009-11-09 | 2019-04-30 | Allergan Inc | Kompozycje i sposoby stymulowania wzrostu włosów |
| AU2014216112B2 (en) | 2013-02-15 | 2019-02-21 | Allergan, Inc. | Sustained drug delivery implant |
| CN108084186B (zh) * | 2016-11-16 | 2021-06-25 | 江苏新元素医药科技有限公司 | Urat1抑制剂及其应用 |
| FI4426434T3 (fi) | 2021-11-02 | 2025-11-24 | Flare Therapeutics Inc | Pparg:n käänteisagonisteja ja niiden käyttöjä |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1720033A1 (de) * | 1966-03-02 | 1971-05-19 | Yoshitomi Pharmaceutical | Neue Indolderivate und Verfahren zu ihrer Herstellung |
| US3485835A (en) * | 1968-04-10 | 1969-12-23 | Haessle Ab | 2-benzoyl-3-tertiaryamino alkoxy benzofuran derivatives |
| IL32186A (en) * | 1968-05-24 | 1974-10-22 | Fisons Ltd | 5-benzofuranyl compounds,their preparation,and physiologically active compositions containing them |
| US3860609A (en) * | 1969-05-27 | 1975-01-14 | Novo Terapeutisk Labor As | 3-aminoalkyloxyindoles |
| US3859305A (en) * | 1970-03-10 | 1975-01-07 | Degussa | Indole aminoketones |
| SE379196B (cs) * | 1971-06-24 | 1975-09-29 | Sandoz Ag | |
| US3947470A (en) * | 1974-06-20 | 1976-03-30 | Smithkline Corporation | Substituted benzofurans and benzothiophenes |
| US4013012A (en) * | 1974-11-18 | 1977-03-22 | Altus Corporation | Electronic safe arming and fuzing system |
| FI61030C (fi) * | 1976-02-19 | 1982-05-10 | Sanofi Sa | Foerfarande foer framstaellning av terapeutiskt verkande 2-substituerade-1- eller 3-benzoyl-indolizinderivat |
| US4117128A (en) * | 1976-08-03 | 1978-09-26 | Smithkline Corporation | Sulfonyl benzofurans and benzothiophenes having coronary vasodilator activity |
| FR2376145A1 (fr) * | 1977-01-03 | 1978-07-28 | Thea Therapeutiques Applic Sa | Nouveaux derives de chromones a activite medicamenteuse et leur preparation |
| GB1560006A (en) * | 1977-08-18 | 1980-01-30 | Laroche Navarron Sa | Benzoyl furan derivatives process for their preparation and therapeutic applications thereof |
| US4128552A (en) * | 1977-09-26 | 1978-12-05 | Warner-Lambert Company | 1-[4,4-Bis(4-fluorophenyl)butyl]-4-phenylthio-1,2,3,6-tetrahydropyridines and related sulfoxides and sulfones |
| JPS59204191A (ja) * | 1983-03-26 | 1984-11-19 | Kyorin Pharmaceut Co Ltd | ピラゾロピリジン誘導体、その製法及びそれを含有する治療剤 |
| US4654360A (en) * | 1984-06-01 | 1987-03-31 | Syntex (U.S.A.) Inc. | 1,2,3-trisubstituted indoles for treatment of inflammation |
| DE3426419A1 (de) * | 1984-07-18 | 1986-01-23 | Boehringer Mannheim Gmbh, 6800 Mannheim | Neue oxindol-derivate, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und zwischenprodukte |
| US4675405A (en) * | 1984-09-21 | 1987-06-23 | American Home Products Corporation | Quinoline compounds as antiallergic and antithrombotic agents |
| FR2584723B1 (fr) * | 1985-07-09 | 1988-02-12 | Adir | Nouveaux derives du dihydro-2,3 benzofuranne, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent |
| DE3531658A1 (de) * | 1985-09-05 | 1987-03-12 | Boehringer Mannheim Gmbh | Heterocyclisch substituierte indole, zwischenprodukte, verfahren zu ihrer herstellung und arzneimittel |
| FR2594438B1 (fr) * | 1986-02-14 | 1990-01-26 | Labaz Sanofi Nv | Derives d'indolizine, leur procede de preparation ainsi que les compositions en contenant |
| US4873259A (en) * | 1987-06-10 | 1989-10-10 | Abbott Laboratories | Indole, benzofuran, benzothiophene containing lipoxygenase inhibiting compounds |
| IL87181A (en) * | 1987-08-07 | 1993-08-18 | Sanofi Sa | Aminoalkoxyphenyl derivatives, their preparation and pharmaceutical and veterinary compositions containing them |
-
1986
- 1986-02-14 FR FR8602045A patent/FR2594438B1/fr not_active Expired - Lifetime
-
1987
- 1987-01-22 ZA ZA87471A patent/ZA87471B/xx unknown
- 1987-01-22 IL IL81358A patent/IL81358A/xx not_active IP Right Cessation
- 1987-01-26 MY MYPI87000061A patent/MY101541A/en unknown
- 1987-02-06 PH PH34827A patent/PH24830A/en unknown
- 1987-02-10 DE DE8787870019T patent/DE3769174D1/de not_active Expired - Lifetime
- 1987-02-10 AT AT87870019T patent/ATE62485T1/de not_active IP Right Cessation
- 1987-02-10 EP EP87870019A patent/EP0235111B1/fr not_active Expired - Lifetime
- 1987-02-10 ES ES198787870019T patent/ES2040276T3/es not_active Expired - Lifetime
- 1987-02-10 BE BE8700103A patent/BE1006666A4/fr not_active IP Right Cessation
- 1987-02-11 IE IE34587A patent/IE59656B1/en not_active IP Right Cessation
- 1987-02-11 CA CA000529512A patent/CA1310965C/en not_active Expired - Lifetime
- 1987-02-12 PT PT84277A patent/PT84277B/pt unknown
- 1987-02-12 AR AR87306719A patent/AR245127A1/es active
- 1987-02-12 PL PL1987264078A patent/PL152609B1/pl unknown
- 1987-02-12 PL PL1987282576A patent/PL153650B1/pl unknown
- 1987-02-13 FI FI870629A patent/FI84353C/fi not_active IP Right Cessation
- 1987-02-13 DK DK074087A patent/DK170403B1/da not_active IP Right Cessation
- 1987-02-13 JP JP62032304A patent/JP2547004B2/ja not_active Expired - Lifetime
- 1987-02-13 NO NO870579A patent/NO165344C/no unknown
- 1987-02-13 SU SU874202058A patent/SU1486064A3/ru active
- 1987-02-13 HU HU87567A patent/HU196401B/hu unknown
- 1987-02-13 NZ NZ219274A patent/NZ219274A/xx unknown
- 1987-02-13 CZ CS87977A patent/CZ281209B6/cs not_active IP Right Cessation
- 1987-02-13 YU YU00212/87A patent/YU21287A/xx unknown
- 1987-02-13 MA MA21112A patent/MA20878A1/fr unknown
- 1987-02-13 SK SK977-87A patent/SK279557B6/sk unknown
- 1987-02-13 OA OA59070A patent/OA08481A/xx unknown
- 1987-02-13 DD DD87299907A patent/DD264436A5/de not_active IP Right Cessation
- 1987-02-14 KR KR870001238A patent/KR870007931A/ko not_active Withdrawn
- 1987-02-16 AU AU68846/87A patent/AU587525B2/en not_active Expired
- 1987-02-19 TN TNTNSN87021A patent/TNSN87021A1/fr unknown
- 1987-08-07 US US07/082,554 patent/US4957925A/en not_active Expired - Lifetime
- 1987-08-11 SU SU4203068A patent/SU1528321A3/ru active
-
1988
- 1988-03-08 YU YU00465/88A patent/YU46588A/xx unknown
-
1989
- 1989-02-06 US US07/306,498 patent/US5017579A/en not_active Expired - Fee Related
- 1989-02-06 US US07/306,499 patent/US4994474A/en not_active Expired - Fee Related
-
1990
- 1990-03-19 US US07/495,134 patent/US5039700A/en not_active Expired - Fee Related
- 1990-04-19 US US07/511,095 patent/US5147878A/en not_active Expired - Fee Related
-
1991
- 1991-04-30 GR GR91400559T patent/GR3001883T3/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SK279557B6 (sk) | Deriváty indolizínu, spôsob ich prípravy a farmace | |
| US4520025A (en) | Bicyclic nitrogen heterocyclic ethers and thioethers, and their pharmaceutical uses | |
| KR0165131B1 (ko) | 1,4-벤조티아제핀 유도체 | |
| PL179255B1 (pl) | N owe pochodne 4-aminopiperydylo-(1 )-benzoiloguanidyny, sposób ich wytwarzania oraz preparat farmaceutyczny PL PL PL PL PL PL PL | |
| PL168044B1 (pl) | Sposób wytwarzania pochodnych benzofuranu, benzotiofenu, indolu lub indolizyny PL PL PL | |
| IE51179B1 (en) | Pyridoxine derivatives,process for preparing them and use in therapeutics | |
| RU2032669C1 (ru) | Способ получения аминофеноксипроизводных | |
| EP0211346B1 (en) | Phenylpiperazine phosphonates | |
| EP0116368A1 (en) | Benzothiazine derivatives | |
| US5444056A (en) | Aminoalkoxyphenyl derivatives, process for their preparation and compositions containing them | |
| US5576327A (en) | Treatment of heart rhythym disorders by administration of 3-phenylsulfonyl-3, 7-diazabicyclo[3.3.1]nonane compounds | |
| EP0168003B1 (en) | Oxindol compounds, compositions containing same and processes for preparing same | |
| US4612309A (en) | Antisecretory bicyclic benzo-oxy heterocyclic ethers and thioethers | |
| KR950007179B1 (ko) | 인돌리진 유도체, 그 약제학적 조성물, 그 용도 및 그 제조방법 | |
| US4777168A (en) | Bicyclic benzo-oxy heterocyclic ethers and thioethers, pharmaceutical compositions and use | |
| JPH0123463B2 (cs) | ||
| US4722925A (en) | Bicyclic benzo-oxy heterocyclic ethers and thioethers pharmaceutical compositions and use | |
| US4668673A (en) | Bicycle benzo-oxy heterocyclic ethers and thioethers, pharmaceutical compositions and use | |
| KR850000260B1 (ko) | 피리독신 유도체의 제조방법 | |
| EP0119540A2 (en) | Substituted alkylamine derivatives of 6,11-dihydro-11-oxodibenz (b,e)-oxepins, a process for the preparation and intermediates thereof and their use as medicaments | |
| HU209753B (en) | Process for producing of 3-(4-nitrophenoxy)-propylamine derivatives and pharmaceutical compositions comprising them | |
| PL155859B1 (pl) | Sposób wytwarzania nowych pochodnych kwasu 1,2,3,4-tetrahydropirymidynokarboksylowego-5 | |
| JPH0517907B2 (cs) |